Results 121 to 130 of about 766,818 (299)

The Fermi Surface Effect on Magnetic Interlayer Coupling

, 2004
The oscillating magnetic interlayer coupling of Fe over spacer layers consisting of Cu$_{x}$Pd$_{1-x}$ alloys is investigated by first principles density functional theory.
Anders Bergman, B. L. Györffy, Erik Holmström, H. Nyquist, I. A. Abrikosov, I. A. Abrikosov, K. Ohshima, K. Wildberger, Lars Nordström, O. Andersen, S. B. Dugdale   +10 more
core   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

PD‐1 targeting in cancer immunotherapy [PDF]

Cancer, 2012
This Web‐only perspective commentary discusses a new class of monoclonal antibodies that have garnered tremendous enthusiasm within the field of cancer immunotherapy, which has previously been hampered by complex, cumbersome agents and cells; individualized and laborious preparations; and questionable clinical efficacy.
openaire   +2 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

LARAMED: A Laboratory for Radioisotopes of Medical Interest

Molecules, 2018
The widespread availability of novel radioactive isotopes showing nuclear characteristics suitable for diagnostic and therapeutic applications in nuclear medicine (NM) has experienced a great development in the last years, particularly as a result of key
Juan Esposito, Diego Bettoni, Alessandra Boschi, Michele Calderolla, Sara Cisternino, Giovanni Fiorentini, Giorgio Keppel, Petra Martini, Mario Maggiore, Liliana Mou, Micòl Pasquali, Lorenzo Pranovi, Gaia Pupillo, Carlos Rossi Alvarez, Lucia Sarchiapone, Gabriele Sciacca, Hanna Skliarova, Paolo Favaron, Augusto Lombardi, Piergiorgio Antonini, Adriano Duatti   +20 more
doaj   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Nivolumab plus ipilimumab in the treatment of advanced melanoma. [PDF]

, 2015
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that
Daud, Adil I, Tsai, Katy K
core   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers

Polish Journal of Pathology
Colorectal cancer is the third most common cancer worldwide and the second cause of death from malignant tumors. Colorectal cancers are treated with surgery, chemotherapy, gene therapy and immunotherapy.
Paulina Poter, Sylwia Jankowska-Szabłowska, Tomasz Kolenda, Ewa Dobak, Elżbieta Urasińska, Katarzyna Karpińska-Łukaszewicz   +5 more
doaj   +1 more source